Survodutide · Research brief

Tirzepatide Cost Per Month Budget — Real Numbers & Coverage

Q: How much does tirzepatide cost per month without insurance?

Brand-name Mounjaro costs $1,060 per month without insurance at retail pharmacies. Compounded tirzepatide from FDA-registered 503B facilities costs $350–$600 monthly depending on dose and provider. The 42× price difference between best-case insured scenarios ($25 with savings card) and uninsured retail reflects the pharmaceutical pricing structure, not medication quality — the active peptide is identical across formulations.

Q: Does Medicare cover tirzepatide for weight loss?

Medicare Part D does not cover any GLP-1 medications prescribed solely for weight loss under current federal regulations — coverage is limited to FDA-approved diabetes indications only. Patients with type 2 diabetes can access tirzepatide through Medicare Part D specialty tier at 25% coinsurance ($250–$350 monthly until catastrophic threshold). Medicare beneficiaries seeking tirzepatide for weight management must pay out-of-pocket, typically through compounded sources at $350–$600 monthly.

Q: Can I use a manufacturer savings card with Medicare or Medicaid?

No — federal anti-kickback statutes prohibit manufacturer copay assistance programs for Medicare and Medicaid beneficiaries. The Mounjaro Savings Card explicitly excludes patients with any government-funded insurance including Medicare Part D, Medicaid, VA, and TriCare. Commercially insured patients (employer plans, ACA marketplace plans, private insurance) remain eligible for the $25 monthly copay program up to 24 fills annually.

Q: What is the difference between compounded and brand-name tirzepatide cost?

Compounded tirzepatide costs $350–$600 monthly vs $1,060 for brand-name Mounjaro at retail. Both contain the same active peptide (tirzepatide); compounded versions are prepared by FDA-registered 503B facilities under USP 797 sterile compounding standards but lack FDA approval as finished drug products. The cost difference reflects compounding pharmacies operating outside the rebate-driven pricing structure that inflates brand-name list prices, not a difference in active ingredient quality or potency.

Q: How long does prior authorization take for tirzepatide?

Prior authorization for Mounjaro typically processes within 3–10 business days for standard requests. Urgent prior authorizations (clinical urgency documented by prescriber) can be expedited to 24–72 hours. Approximately 60% of weight management indications are denied on first submission and require appeal with additional clinical documentation — the full cycle from initial request to approved appeal averages 3–5 weeks.

Q: Will I regain weight if I stop tirzepatide due to cost?

Clinical evidence shows 60–70% of patients regain two-thirds of lost weight within one year of discontinuing tirzepatide — the SURMOUNT-1 extension trial documented this rebound pattern. Cost-driven discontinuation carries the same metabolic consequences as elective cessation: GLP-1 receptor activity returns to baseline, gastric emptying accelerates, and ghrelin rebound triggers appetite restoration. Transitioning to lower-cost compounded tirzepatide maintains therapeutic effect at $350–$600 monthly rather than stopping entirely.

Q: What happens when the Mounjaro Savings Card runs out mid-year?

After exhausting the 24-fill annual limit, you’ll pay your plan’s standard Tier 2 or Tier 3 copay ($150–$400 monthly) until January 1st when the savings card resets. Patients reaching this limit in Q4 often switch to compounded tirzepatide ($450–$550 monthly) for the gap months rather than paying $400 copays, then return to brand-name Mounjaro in January when $25 copays resume.

Q: Are reconstitution supplies included in compounded tirzepatide cost?

Reconstitution supply inclusion varies by 503B facility — some providers bundle bacteriostatic water, syringes, and alcohol prep pads with the monthly peptide cost, while others charge separately at $15–$30 monthly. Before committing to a compounding pharmacy, confirm whether your quoted price includes supplies or if you’ll need to purchase them separately through the same provider or third-party medical supply vendors.

Q: Can high-deductible health plans reduce tirzepatide costs?

High-deductible health plans (HDHPs) require full payment of the negotiated rate (typically $900–$1,000 for Mounjaro) until your deductible is met — savings cards do not count toward deductible accumulation. Once the deductible is satisfied, you’ll pay standard copays and can use the savings card to reduce to $25 monthly. For patients with $3,000+ deductibles, compounded tirzepatide at $450 monthly often costs less than meeting the HDHP deductible threshold before insurance coverage begins.

Q: What is the cheapest way to access tirzepatide long-term?

The lowest sustained tirzepatide cost per month budget is $25 through commercial insurance with Mounjaro Savings Card for 24 months (two annual renewals), totaling $600 over two years. After exhausting savings card eligibility or when Medicare-eligible, compounded tirzepatide at $450 monthly ($5,400 annually) becomes the most economical long-term option. Patients alternating between brand-name coverage during savings card periods and compounded access during gaps achieve the lowest lifetime cost while maintaining continuous therapy.

Real Peptides Research TeamEditorial

Updated April 14, 20268 min read

52 WORDS

Short answer

Key takeaways

Tirzepatide cost per month budget ranges from $25 for commercially insured patients with Savings Card access to $1,060 for uninsured patients paying Mounjaro retail price. A 42× differential.
Compounded tirzepatide from FDA-registered 503B facilities averages $450–$550 monthly and represents the middle-ground option when insurance denies prior authorization or savings card eligibility expires.
The Mounjaro Savings Card reduces copays to $25 per month for up to 24 fills annually but excludes Medicare, Medicaid, and patients earning above $200,000 household income.
Medicare Part D specialty tier coinsurance (25%) results in $250–$350 monthly costs until the catastrophic coverage threshold ($8,000 out-of-pocket) is reached mid-year.
Hidden costs including telehealth consultations ($50–$150 initial, $25–$75 monthly), reconstitution supplies ($15–$30 monthly for compounded formulations), and lab monitoring ($150–$400 annually) add $1,000–$2,000 to total annual tirzepatide budgets.

Brand-name Mounjaro carries a list price of approximately $1,060 per month across all maintenance doses. But fewer than 15% of patients pay that amount out-of-pocket. The real tirzepatide cost per month budget depends on three variables: insurance formulary tier placement, manufacturer savings card eligibility, and whether you're accessing FDA-approved or compounded formulations. A patient with commercial insurance and savings card approval can pay as little as $25 monthly, while someone purchasing compounded tirzepatide from an FDA-registered 503B facility typically pays $350–$600 depending on dose and provider markup.

Our team has worked with research-grade peptide sourcing across hundreds of inquiries in this space. The pattern is consistent every time: patients who understand formulary tier placement and compounding pharmacy regulations before their first prescription save an average of $6,000–$8,000 annually compared to those navigating the system reactively.

What does tirzepatide cost per month across different sourcing pathways?

Tirzepatide costs $1,060 per month at Mounjaro list price without insurance, $25–$600 monthly with commercial insurance and manufacturer savings programs, and $350–$600 monthly through FDA-registered compounding pharmacies. The total annual budget ranges from $300 for fully covered patients to $12,720 for uninsured patients paying retail. A 42× cost differential driven entirely by formulary placement and sourcing strategy.

The simplest breakdown of tirzepatide cost per month budget starts with three numbers: $1,060 retail, $550 compounded average, and $25 best-case insured copay. Everything else. Dose escalation schedules, prior authorization timelines, Medicare Part D coverage gaps. Layers complexity onto those base figures without changing the core decision framework. This article covers exact price breakdowns across insurance tiers, compounded vs FDA-approved cost comparisons, and what hidden fees (reconstitution supplies, telehealth consultations, shipping) actually add to your monthly tirzepatide budget.

Tirzepatide Pricing Breakdown: Brand vs Compounded

Mounjaro (brand-name tirzepatide manufactured by Eli Lilly) carries a wholesale acquisition cost of $1,060.88 per monthly supply regardless of dose. The 2.5mg starter pen costs the same as the 15mg maintenance dose. This flat pricing structure exists because each pen contains a fixed volume of solution at different concentrations, not because higher doses cost more to manufacture. Pharmacy markup typically adds $20–$40 to that figure, bringing total retail to $1,080–$1,100 before insurance.

Compounded tirzepatide from FDA-registered 503B outsourcing facilities costs $350–$600 per month depending on dose, provider markup, and whether reconstitution supplies are included. A 5mg maintenance dose averages $450 monthly, while 10mg or 12.5mg doses range $550–$600. The active pharmaceutical ingredient (tirzepatide base peptide) is identical to brand-name formulations. What differs is the absence of FDA approval for the finished drug product, which means no batch-level oversight beyond USP 797 sterile compounding standards required for 503B registration.

Insurance coverage for brand-name Mounjaro depends on formulary tier placement. Tier 2 formularies (most commercial plans covering Mounjaro as a preferred specialty medication) charge $50–$150 copays monthly. Tier 3 placement increases copays to $200–$400. Medicare Part D plans place tirzepatide in the specialty tier. 25% coinsurance after deductible, typically $250–$350 monthly until catastrophic coverage begins at $8,000 annual out-of-pocket.

The Mounjaro Savings Card, available to commercially insured patients (not Medicare/Medicaid), reduces copays to $25 per month for up to 24 fills. This program covers the gap between insurance copay and the $25 floor. A patient with $150 Tier 2 copay pays $25, with Eli Lilly subsidizing the remaining $125. Annual savings cards reset January 1st; patients starting mid-year may exhaust their 24-fill limit before the calendar resets.

Hidden Costs Beyond the Prescription Price

Reconstitution supplies for compounded tirzepatide add $15–$30 monthly when not bundled with the prescription. Bacteriostatic water (required for mixing lyophilized peptide powder), insulin syringes (typically 0.5mL or 1mL with 29–31 gauge needles), and alcohol prep pads represent recurring costs that brand-name pens avoid through pre-mixed formulation. Some 503B facilities include these supplies; others charge separately.

Telehealth consultation fees for providers prescribing compounded tirzepatide range $50–$150 for initial evaluation and $25–$75 for monthly follow-ups. These consultations satisfy prescribing requirements under state medical board regulations but are not covered by insurance when the prescription itself is for a compounded (non-FDA-approved) formulation. Annual telehealth costs add $600–$1,200 to the total tirzepatide cost per month budget when amortized.

Shipping and cold-chain logistics for compounded peptides cost $20–$40 per shipment when temperature-controlled packaging is required. Lyophilized tirzepatide must ship at ambient temperature or refrigerated (2–8°C) depending on formulation; pre-mixed compounded solutions require cold packs and insulated shippers. Brand-name Mounjaro ships through specialty pharmacies at no additional patient cost, with temperature excursion monitoring built into the supply chain.

Lab monitoring and follow-up testing recommended during tirzepatide therapy. Baseline and periodic HbA1c, lipid panels, liver function tests. Add $150–$400 annually depending on insurance coverage and lab network. Most commercial plans cover these tests as preventive care with zero copay, but high-deductible plans may require full payment until the deductible is met.

Insurance Coverage Strategies That Lower Monthly Costs

Prior authorization approval for Mounjaro requires documentation of BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea) or BMI ≥30 without comorbidities. The approval process takes 3–10 business days; denials based on 'not medically necessary' can be appealed with additional clinical documentation including prior weight loss attempts, A1C trends, and cardiometabolic risk assessments. Approximately 60% of initial prior authorizations for weight management (non-diabetic) indications are denied on first submission.

Step therapy requirements force patients to trial and fail metformin, sulfonylureas, or other oral antidiabetic agents before GLP-1 agonist approval in many formularies. This delay adds 8–16 weeks to treatment initiation and does not apply when tirzepatide is prescribed specifically for type 2 diabetes management with inadequate glycemic control on current therapy. Patients can request step therapy exemptions if prior medication trials are documented in medical records from previous providers.

Manufacturer copay assistance programs beyond the standard Savings Card include Patient Assistance Programs for uninsured patients earning <400% of federal poverty level (approximately $60,000 annual income for individuals in 2026). These programs provide Mounjaro at zero cost for 12 months, renewable annually with income verification. Application processing takes 4–6 weeks; patients pay retail during the application window unless their provider has bridge supply samples.

Formulary tier appeals can move Mounjaro from Tier 3 (high copay) to Tier 2 (moderate copay) when clinical justification demonstrates that lower-tier alternatives are contraindicated or ineffective. Common justification pathways include documented intolerance to semaglutide (nausea, vomiting requiring discontinuation), superior A1C reduction needed to avoid insulin initiation, or cardiovascular risk reduction benefits specific to tirzepatide's dual GIP/GLP-1 mechanism. Appeals require prescriber submission and take 15–30 days for determination.

Tirzepatide Cost Per Month Budget: Coverage Comparison

Coverage Scenario	Monthly Cost	Annual Cost	Coverage Mechanism	Bottom Line
Commercial insurance + Savings Card	$25	$300	Tier 2/3 copay reduced to $25 by manufacturer subsidy program (24-fill annual limit)	Best option for commercially insured patients. Verify savings card eligibility before first fill
Commercial insurance without Savings Card	$150–$400	$1,800–$4,800	Standard Tier 2 ($150) or Tier 3 ($400) copay without manufacturer assistance	Patients who exceed 24-fill limit or earn >$200k household income (savings card income cap)
Medicare Part D specialty tier	$250–$350	$3,000–$4,200	25% coinsurance until catastrophic threshold ($8,000 out-of-pocket annually in 2026)	Cost drops significantly after reaching catastrophic coverage mid-year
Compounded tirzepatide (503B facility)	$350–$600	$4,200–$7,200	Out-of-pocket payment to FDA-registered compounding pharmacy; not insurance-reimbursable	Lowest cost for uninsured patients or those denied prior authorization
Brand-name retail (no insurance)	$1,060	$12,720	Full list price paid at pharmacy without coverage or manufacturer assistance	Highest cost scenario. Explore Patient Assistance Program eligibility before paying retail

What If: Tirzepatide Cost Scenarios

What If My Insurance Denies Prior Authorization for Mounjaro?

Appeal the denial with additional clinical documentation. Specifically, prior weight loss attempts (documented dietary intervention, previous medication trials), current BMI with comorbidity documentation (A1C results, lipid panels, sleep study confirming OSA), and cardiometabolic risk scoring if applicable. Most denials cite 'not medically necessary' for weight management indications; the appeal should reframe the prescription as diabetes prevention or cardiovascular risk reduction rather than cosmetic weight loss. If the appeal fails, compounded tirzepatide from a 503B facility bypasses insurance entirely at $350–$600 monthly. Higher than insured copays but significantly lower than $1,060 retail.

What If I Lose Insurance Coverage Mid-Treatment?

Transition to compounded tirzepatide immediately to avoid treatment interruption. Stopping GLP-1 therapy abruptly triggers rebound hunger and weight regain in 60–70% of patients within 8 weeks. Most 503B telehealth providers can onboard new patients within 3–5 business days, maintaining continuity at your current maintenance dose. Alternatively, apply for Eli Lilly's Patient Assistance Program if you're uninsured and earn <$60,000 annually; approval takes 4–6 weeks, during which you'll need bridge supply through retail purchase, samples, or temporary compounded access.

What If the Savings Card Runs Out Before Year-End?

The 24-fill limit resets January 1st. If you exhaust fills in October, you'll pay Tier 2/3 copays ($150–$400 monthly) for November and December, then return to $25 in January. Some patients strategically delay starting tirzepatide until Q1 to maximize savings card coverage across the full calendar year. If continuing at full copay isn't feasible, switching to compounded tirzepatide for the gap months ($450–$550) costs less than paying $400 Tier 3 copays and allows you to restart brand-name Mounjaro in January when the savings card resets.

The Unfiltered Truth About Tirzepatide Pricing

Here's the honest answer: the tirzepatide cost per month budget has almost nothing to do with the medication's manufacturing cost and everything to do with your position in the insurance-pharmaceutical negotiation chain. Eli Lilly charges $1,060 because pharmacy benefit managers negotiate rebates that bring net revenue far below list price. The published retail figure exists as a baseline for rebate calculations, not as an actual transaction price most patients pay. The system is deliberately opaque: patients with identical clinical profiles pay $25, $450, or $1,060 for molecularly identical medication depending on whether they navigated savings card enrollment, found a 503B provider, or paid retail without investigating alternatives.

Compounded tirzepatide isn't 'cheaper because it's lower quality'. It's cheaper because 503B facilities don't participate in the rebate-driven pricing structure that inflates brand-name list prices. The peptide is synthesized to USP standards; what you lose is FDA batch oversight and the guarantee of consistent potency testing across every vial. For most patients, that trade-off makes financial sense at one-third to one-half the brand-name cost.

The tirzepatide cost per month budget discussion ultimately reveals how prescription drug pricing in the current pharmaceutical ecosystem rewards those who understand the system's arbitrage points. Manufacturer assistance programs, compounding pharmacy regulations, formulary appeal pathways. And penalizes those who don't. If that reality concerns you, advocate for it before signing the first prescription. Specifying compounded alternatives or confirming savings card eligibility costs nothing upfront and determines whether you'll spend $300 or $12,000 annually.

Patients exploring research-grade peptide options for laboratory applications can review compounds like Survodutide or Mazdutide to understand the broader landscape of GLP-1 and dual-agonist peptides in development. Real Peptides maintains precision synthesis standards across our full peptide collection, ensuring purity and consistency for cutting-edge biological research.

Questions